Questions and Caveats in Antigen-Defined Membranous Nephropathy.

Area of Science:

• Nephrology
• Immunology
• Pathology

Background:

• Significant advancements in identifying autoantigens for membranous nephropathy (MN).
• Routine testing for MN autoantigens necessitates understanding their clinical associations.
• Clinical interpretation of MN autoantigen test results presents challenges.

Purpose of the Study:

• To review critical considerations and potential discrepancies in interpreting membranous nephropathy autoantigen testing.
• To explore the nuanced relationships between specific autoantigens and clinical conditions in MN.
• To discuss implications for diagnosis and treatment based on autoantigen profiles.

Main Methods:

• Literature review focusing on autoantigens in membranous nephropathy.
• Analysis of clinical scenarios and diagnostic discrepancies related to autoantigen testing.
• Examination of antigen heterogeneity and co-occurrence in MN.

Main Results:

• Discrepancies exist between tissue-detected antigens and clinical presentation, notably with phospholipase A2 receptor (PLA2R).
• A single antigen can be linked to diverse clinical conditions, and conversely, a single condition may involve multiple antigens (e.g., sarcoidosis, NELL-1).
• Co-occurrence of multiple MN-associated antigens (e.g., anti-PCDH7) in tissue or blood is rare but significant.
• Lupus membranous nephritis involves specific antigens influencing diagnosis and treatment.

Conclusions:

• Interpreting membranous nephropathy autoantigen tests requires careful consideration of antigen-specific clinical associations.
• Understanding antigen heterogeneity and potential co-occurrence is crucial for accurate diagnosis and management.
• Further research is needed to refine the diagnostic and therapeutic utility of autoantigen testing in MN.